Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-1091 in Advanced Solid Tumors
NCT05675605Phase 2Recruiting
- Sponsor
- TYK Medicines
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TY-1091 in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), papillary thyroid cancer (PTC) and 1 more (2 arms), sponsored by TYK Medicines. Primary endpoints: Dose Limiting Toxicity at 25 days, Adverse Events at 12 months and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
TY-1091
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)papillary thyroid cancer (PTC)solid tumor
Beyond the preview
Go deeper on NCT05675605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675605.